Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Regen BioPharma, Inc.
  6. News
  7. Summary
    RGBP   US75886M1027

REGEN BIOPHARMA, INC.

(RGBP)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

REGEN BIOPHARMA INC : Entry into a Material Definitive Agreement (form 8-K)

04/16/2021 | 03:53pm EDT

Item 1.01 Entry into a Material Definitive Agreement

On December 16, 2019 Zander Therapeutics, Inc. ("Zander"), KCL Therapeutics, Inc. ("KCL") and Regen Biopharma, Inc. ("Regen") entered into an agreement ("Agreement") whereby:

1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen ("Conversion Shares") acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement.

2) A $35,000 one time charge due to Zander by Regen ("One Time Charge") shall be applied pursuant to the Agreement.

3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.

No actions were taken by any of the parties to enforce the terms of the Agreement.

On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:

a) Zander shall not return the Conversion shares for cancellation and the

principal indebtedness of the aforementioned convertible note shall not

reflect such return

b) As of December 16, 2019 all principal and accrued interest payable by Regen to

    Zander on that date resulting from Promissory Notes issued by Regen to Zander
    shall be credited towards amounts due by Zander pursuant to that agreement, as
    amended, entered into by and between Zander and Regen on June 23, 2015
    ("License Agreement") whereby Regen granted to Zander an exclusive worldwide
    right and license for the development and commercialization of certain
    intellectual property controlled by Regen for non-human veterinary therapeutic
    use for a term of fifteen years and that License Assignment And Consent
    agreement entered into by and between Regen, KCL and Zander on December 17,
    2018 whereby Regen transferred and assigned to KCL all rights, duties, and
    obligations of Regen under the License Agreement and KCL agreed to assume such
    duties and obligations thereunder and be bound to the terms of the License
    Agreement with respect thereto.



The foregoing description of the abovementioned Agreement is not complete and is qualified in its entirety by reference to the text of the abovementioned agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference. Regen, KCL and Zander are under common control. David Koos serves as sole Officer and Chairman of the Board of Zander, Regen and KCL.

Item 9.01 Exhibits.

Exhibit No.   Description of Exhibit
10.1            AMENDMENT




2

© Edgar Online, source Glimpses

All news about REGEN BIOPHARMA, INC.
05/07REGEN BIOPHARMA INC  : Other Events (form 8-K)
AQ
04/27REGEN BIOPHARMA INC  : Unregistered Sale of Equity Securities, Material Modifica..
AQ
04/21REGEN BIOPHARMA INC  : Other Events (form 8-K)
AQ
04/19REGEN BIOPHARMA INC  : Other Events (form 8-K)
AQ
04/16REGEN BIOPHARMA INC  : Entry into a Material Definitive Agreement (form 8-K)
AQ
04/09REGEN BIOPHARMA INC  : Other Events (form 8-K)
AQ
04/08REGEN BIOPHARMA INC  : Entry into a Material Definitive Agreement (form 8-K)
AQ
03/30REGEN BIOPHARMA INC  : Other Events (form 8-K)
AQ
03/25REGEN BIOPHARMA INC  : Change in Directors or Principal Officers, Entry into a M..
AQ
2020BIO MATRIX SCIENTIFIC  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
More news
Financials (USD)
Sales 2018 0,10 M - -
Net income 2018 -4,72 M - -
Net Debt 2018 1,42 M - -
P/E ratio 2018 -0,38x
Yield 2018 -
Capitalization 14,4 M 14,4 M -
EV / Sales 2017 62,7x
EV / Sales 2018 34,9x
Nbr of Employees 3
Free-Float 100%
Chart REGEN BIOPHARMA, INC.
Duration : Period :
Regen BioPharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
David Raymond Koos Chairman, President, CEO, Secretary & Treasurer
Sector and Competitors
1st jan.Capitalization (M$)
REGEN BIOPHARMA, INC.1,870.00%14
GILEAD SCIENCES, INC.14.21%83 778
VERTEX PHARMACEUTICALS-9.03%55 659
WUXI APPTEC CO., LTD.6.21%54 226
REGENERON PHARMACEUTICALS3.22%51 442
BIONTECH SE125.36%44 370